Sanofi SA
featured
Patent expirations on big-name drugs has resulted in modestly less spending on medicines in the U.S. for the first time in at least 55 years, a report showed Thursday.
» Read More
.160x105.jpg?v=1366904651 "Fed Could Give Market a Safety Net")
More
-
NEW YORK-- Shares of Amyris Inc. fell Thursday after a law firm said it has filed a federal securities class action lawsuit against the company, saying Amyris misled investors about its production capabilities. THE SPARK: Milberg LLP said its lawsuit will include investors who bought Amyris securities between April 29, 2011 and Feb. 8, 2012.
-
The FDA in January asked zolpidem manufacturers, including NovaDel Pharma Inc and Swedish drugmaker Meda, to reduce recommended dosages on the drugs' labels. The FDA recommended doses of 5 mg for women and either 5 mg or 10 mg for men for immediate-release zolpidem products such as Sanofi's Ambien.
-
*Defensive stocks unusually leading Europe stock rally. LONDON, May 14- Defensive stocks such as healthcare companies, which often bring up the rear when markets rise, have led the gainers in 2013 as European bourses hit their highest in years, suggesting investors don't think the good times will roll for long.
-
Patent expirations on big-name drugs has resulted in modestly less spending on medicines in the U.S. for the first time in at least 55 years, a report showed Thursday.
-
*Sanofi turns ex-dividend, weighs on France's CAC 40. "We're seeing excessive optimism, with more and more retail investors turning bullish, which is never a good sign," said Guillaume Dumans, co-ahead of 2 Bremans, a Paris- based research firm using behavioural finance to monitor investor sentiment.
-
May 9- Patent expirations on big-name drugs such as Lipitor and Plavix has resulted in modestly less spending on medicines in the United States for the first time in at least 55 years, according to a report released on Thursday.
-
*Novo expects liraglutide for obesity to cost some $20/ day. Chief Executive Lars Sorensen told the Reuters Health Summit on Tuesday that success for a new obesity drug or a green light for long-acting insulin Tresiba- based on interim data from a safety study demanded by regulators- could keep Novo on track.
-
*Risks include high valuation, competitive threats By Ransdell Pierson. TARRYTOWN, N.Y., May 7- Just two years ago, Regeneron Pharmaceuticals was a relatively obscure biotech company in the village of Tarrytown, a picturesque New York suburb better known for "Rip Van Winkle," "The Legend of Sleepy Hollow," and other creations of hometown author Washington Irving.
-
*Shares jump five-fold in two years, market value $26 bln. TARRYTOWN, N.Y., May 7- Just two years ago, Regeneron Pharmaceuticals was a relatively obscure biotech company in the village of Tarrytown, a picturesque New York suburb better known for "Rip Van Winkle," "The Legend of Sleepy Hollow," and other creations of hometown author Washington Irving.
-
*Helvea raises target price to 91 euros from 82 euros; rating accumulate. For a summary of rating actions and price target changes on European companies:. Reuters Station users, click. 1580.
-
*Established drug products in focus at Pfizer, GSK, Sanofi. Bankers speaking at the Reuters Health Summit said the success of transactions such as Pfizer Inc's divestitures of noncore assets and Abbott Laboratories splitting off its innovative drugs into AbbVie Inc had fuelled a wider rethink across the industry.
-
*Nielsen Holdings Nv: Bernstein raises target price to $38 from $36;. *Time Warner Inc: Bernstein raises target price to $63 from $60;. *Viacom Inc: Bernstein raises target price to $64 from $58; rating.
-
*Aiming to win bigger slice of growing market* Lilly currently No.4 in $40 bln diabetes market* Lilly says mainly addressing GPs, not specialists By Ludwig Burger and Frank Siebelt. FRANKFURT, May 3- Eli Lilly, the world's fourth-largest diabetes drugs maker, aims to have the widest range of anti diabetic drugs in order to win a larger slice in the growing market.
-
FRANKFURT, May 3- Eli Lilly, the world's fourth-largest diabetes drugs maker, aims to have the widest range of anti diabetic drugs in order to win a larger slice in the growing market.
-
May 3- Scripps Networks Interactive Inc:. For a summary of rating and price target changes on U.S. companies: Reuters Eikon users, click on RCH/US Reuters 3000 Xtra users, double-click RCH/US Reuters Station users, click. 1568.
-
May 3- Scripps Networks Interactive Inc:. *RBC raises target price to $72 from $68; rating outperform. Reuters Station users, click. 1568.
-
May 3- Scripps Networks Interactive Inc:. *Wunderlich raises price target to $77 from $72; rating buy. Reuters Station users, click. 1568.
-
*Pfizer, Amgen, AstraZeneca among firms placing bets. LONDON, May 3- Is nanomedicine the next big thing? Three deals struck this year by privately held Bind Therapeutics, together worth nearly $1 billion if experiments are successful, highlight a new interest in using such tiny carriers to deliver drug payloads to specific locations in the body.
-
*Pfizer, Amgen, AstraZeneca among firms placing bets. LONDON, May 3- Is nanomedicine the next big thing? Three deals struck this year by privately held Bind Therapeutics, together worth nearly $1 billion if experiments are successful, highlight a new interest in using such tiny carriers to deliver drug payloads to specific locations in the body.
-
May 3- Scripps Networks Interactive Inc:. *MKM Partners raises target price to $80 from $70; rating buy. Reuters Station users, click. 1568.